

Review

Open Access

Chinese medicines as a resource for liver fibrosis treatment

Yibin Feng¹, Kwok-Fan Cheung², Ning Wang¹, Ping Liu³,
Tadashi Nagamatsu⁴ and Yao Tong*¹

Address: ¹School of Chinese Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong, PR China, ²Department of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, PR China, ³Department of Cell Biology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, PR China and ⁴Department of Pharmacobiology and Therapeutics, Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tenpakuku, Nagoya 468-8503, Japan

Email: Yibin Feng - yfeng@hku.hk; Kwok-Fan Cheung - kwokfan@hkusua.hku.hk; Ning Wang - nwang@hkusua.hku.hk; Ping Liu - liuliver@online.sh.cn; Tadashi Nagamatsu - nagamats@ccmfs.meijo-u.ac.jp; Yao Tong* - tongyao@hku.hk

* Corresponding author

Published: 20 August 2009

Received: 2 April 2009

Chinese Medicine 2009, 4:16 doi:10.1186/1749-8546-4-16

Accepted: 20 August 2009

This article is available from: <http://www.cmjournal.org/content/4/1/16>

© 2009 Feng et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Liver fibrosis is a condition of abnormal proliferation of connective tissue due to various types of chronic liver injury often caused by viral infection and chemicals. Effective therapies against liver fibrosis are still limited. In this review, we focus on research on Chinese medicines against liver fibrosis in three categories, namely pure compounds, composite formulae and combination treatment using single compounds with composite formulae or conventional medicines. Action mechanisms of the anti-fibrosis Chinese medicines, clinical application, herbal adverse events and quality control are also reviewed. Evidence indicates that some Chinese medicines are clinically effective on liver fibrosis. Strict quality control such as research to identify and monitor the manufacturing of Chinese medicines enables reliable pharmacological, clinical and in-depth mechanism studies. Further experiments and clinical trials should be carried out on the platforms that conform to international standards.

Background

Liver fibrosis is a condition of abnormal proliferation of connective tissue due to various types of chronic liver injury often caused by viral infection and chemicals. Hepatitis B viral (HBV) infection is the major cause of liver fibrosis in China, whereas hepatitis C viral (HCV) infection and alcohol are the main causes in the United States, Europe and Japan [1-4]. Liver fibrosis may progress into liver cirrhosis and other complications coupled with carcinogenesis [5,6]. The pathogenesis of liver fibrosis involves the activation of hepatic stellate cells (HSCs), the over-expression and over-secretion of collagens, and consequently an excessive accumulation of extracellular matrix (ECM) proteins [7]. Research has been focused on

the management of liver fibrosis including the elimination of primary diseases, immunomodulation, suppression of hepatocyte inflammation, prevention of death and damage of hepatocytes, inhibition of over-secretion and accumulation of ECM proteins, promotion of ECM degradation, improvement of microcirculation and metabolism of liver and reduction of complications [8]. The reversal of liver fibrosis and even cirrhosis has been documented [9].

Complementary and alternative treatments of liver fibrosis have been under active research worldwide [10-12]. In Chinese medicine, liver fibrosis is thought to be caused by 'poor blood circulation, toxin stagnation and a deficiency

of healthy energy' (dysregulated metabolism). Thus, Chinese medicine therapy to treat liver fibrosis is mainly based on reducing blood stagnation, resolving stasis, eliminating toxins and enhancing body immunity.

This review aims to provide an overview on the types of Chinese medicines used to treat liver fibrosis.

Chinese medicines used to treat liver fibrosis

Compounds and extracts

Around 20 compounds or extracts from Chinese medicines have been reported to have liver protective and anti-fibrotic effects. Various studies on their chemistry and pharmacology as well as clinical trials have been carried out to study these compounds or extracts. Table 1 summarizes those with liver protection and anti-fibrotic effects demonstrated in various research reports [13-68].

Composite formulae

More than ten composite formulae for liver fibrosis have been reported [69-108]. Table 2 summarizes traditional composite formulae such as *Yinchenhao Tang*, *Xiao Chaihu Tang*, *Buzhong Yiqi Tang* and *Renshen Yangrong Tang* as well as modern formulae such as *Fufang Jinsane*, *Danshen Taoxiong Tang*, *Ershen Zezhu Tang*, *Buqi Jianzhong Tang*, *Fangji Tang*, *Handan Ganle*, *Ganzhifu* and *Fuzheng Huayu*.

Combination therapy

Studies [109-118] show that combination therapy improves clinical anti-fibrotic effects by using a single compound with composite formulae or Chinese medicines with conventional medicines (Table 3).

Action mechanisms of Chinese medicines in treating liver fibrosis

Inhibition of viral replication

HBV and HCV infections account for most liver cirrhosis and primary liver cancer worldwide [6]. Certain Chinese medicines are anti-HBV and anti-HCV. Berberine markedly reduces viral production *in vitro* but is toxic to host cells [51]. Artemisinin and artesunate strongly inhibit viral production at concentrations that do not affect host cell viability; artesunate and lamivudine exhibit synergistic anti-HBV effects [51]. Another study shows that ascucubin inhibits HBV replication [63]. Nobiletin, the active ingredient of *Citrus unshiu* peel, has anti-HCV effects [94]. Clinical studies show that oxymatrine [28] is effective in reducing hepatitis B viral replication in patients with chronic hepatitis B. *Xiao Chaihu Tang* enhances production of interferon-gamma (IFN- γ) and antibodies against hepatitis B core and e antigen by peripheral blood mononuclear cells (PBMC) in patients with chronic hepatitis [82]. *Handan Ganle* inhibits viral DNA replication in patients with decompensated cirrhosis thereby leading to clinical improvement [102].

Immunomodulation action

Buzhong Yiqi Tang and *Renshen Yangrong Tang* demonstrate immunomodulation effects [91]. In a study on porcine serum-induced liver fibrosis in rats [92], Interleukin 13 (IL-13) levels are positively correlated with hydroxyproline (Hyp) contents in the liver. *Buzhong Yiqi Tang* and *Renshen Yangrong Tang* significantly suppress the increase of hepatic Hyp, while *Xiao Chaihu Tang* does not. Short-term and long-term studies [93] show that *Renshen Yangrong Tang* is effective in liver fibrosis. Further studies find that *Renshen Yangrong Tang* inhibits HCV infection, and that Gomisin A, an active component in the formula's *Schisandra* fruit, exhibits protective effects on immunological hepatopathy [94].

Anti-oxidation and anti-inflammation actions

Salvia miltiorrhizae (*Danshen*) extract [13] improves serum superoxide dismutase (SOD) activity and reduces malondialdehyde (MDA) content in both carbon tetrachloride (CCl₄) and dimethylnitrosamine (DMN) induced hepatic fibrosis rat models. *Salvia miltiorrhizae* extract [18] increases hepatic glutathione levels and decreases peroxidation products in a dose-dependent manner. Taurine [27,28] reduces oxidative stress and prevents progression of hepatic fibrosis in CCl₄-induced hepatic damaged rats and inhibits transformation of the hepatic stellate cell (HSC). In chronic ethanol-induced hepatotoxicity or CCl₄-induced rat liver fibrosis, *Panax notoginseng* (*Tianqi*) extract or total saponin extracted from *Panax notoginseng* reduces the generation of MDA, scavenges free radicals, increases liver and serum SOD content and reduces the accumulation of body lipid peroxide [44-46]. *Ginkgo biloba* (*Yinxing*) extract [49,50] and berberine [54,55,60] exhibit anti-oxidation effects and suppress nuclear factor κ B (NF- κ B) in rats or cell culture. *Yinchenhao Tang* is used to treat liver fibrosis and portal hypertension through suppressing the activated HSC function by genipin, an absorbed form of its component, in CCl₄-or pig-serum-induced rat liver fibrosis [72]. Lin *et al.* [68] find that the hepatoprotective effect of *Solanum nigrum* Linn extract on CCl₄-induced liver fibrosis is achieved through blocking oxidative stress. *Xiao Chaihu Tang* [76,83,85] whose active components baicalin and baicalein function as a potent fibrosis suppressant via the inhibition of the oxidative stress in hepatocyte and HSC. *Handan Ganle* [99] is effective in protecting against liver fibrosis by inhibiting lipid peroxidation in hepatocytes and HSC *in vivo*.

Regulation of cytokines, collagen metabolism and inhibition of HSC

The fibrogenic process is regulated by TGF- β 1 and the specific blockade of TGF- β 1/Smad3 signalling may therapeutically intervene in the fibrosis of various tissues [119]. Most of the Chinese medicines listed in Tables 1 and 2

Table 1: Anti-fibrosis effect of compounds or extracts derived from Chinese medicines

Compounds or extracts and major references	Pharmacological actions and clinical indications	Botanic source
<i>Salvia miltiorrhiza</i> Extract & SA-B [13-18]	Reduce ALT and AST activities, inhibit protein expressions of TGF- β 1, type I collagen and Smad3, anti-oxidation, down-regulate TGF- β 1, TIMP-1 gene expression and MAPK activity, anti-nitric oxide, anti-apoptosis, apply to CHB patients	Root of <i>Salviae miltiorrhiza</i> Bge.
Glycyrrhizin [19-26]	Reduce ALT and AST activities, inhibit NF- κ B binding activity, down-regulate smurf2 gene expression, apply to CHC patients and prevent hepatocarcinoma in patients with HCV-associated cirrhosis	Rhizome of <i>Glycyrrhiza uralensis</i> Fisch., <i>Glycyrrhiza inflata</i> Batal. or <i>Glycyrrhiza glabra</i> L.
Tetrandrine [27-32]	Down-regulate c-fos and c-jun gene expression, anti-nitric oxide, up-regulate Smad7 gene expression, apply to CHB patients, down-regulate NF- κ B signalling cascade and biomarker such as ICAM-1 and α -SMA	Root of <i>Stephaniae tetrandrae</i> S. Moore
Matrine & Oxymatrine [33-35]	Inhibit PDGF and TGF- β 1 actions, inhibit HBV-DNA, improve liver function in patients with CHB or CHC patients	Root of <i>Sophorae flavescens</i> Ait
Taurine [36,37]	Inhibit TGF- β 1 action, collagen formation in M cell culture system, reduce oxidative stress	<i>Calculus Bovis</i>
Tetramethylpyrazine (Chuanxiongazine) [38]	Anti-oxidation, synergic anti-hepatic fibrosis effect with rehlin, apply to CHB patients	Rhizome of <i>Ligusticum chuanxiong</i> Hort.
Rehin, emodin [39-41]	Inhibit TGF- β 1 expression, anti-HSC proliferation	Root and Rhizome of <i>Rheum palmatum</i> L., <i>Rheum tanguticum</i> Maxim. Ex Balf. or <i>Rheum officinale</i> Baill.
Curcumin [42,43]	Anti-oxidative effect, activate PPAR γ to reduce cell proliferation, induce apoptosis and suppress ECM gene expression <i>in vitro</i> and <i>in vivo</i>	Rhizome of <i>Curcumae longa</i> L.
<i>Panax Notoginseng</i> saponin and its water-extract [44-46]	Reduce AST and ALT, increase liver and serum SOD, reduce serum liver fibrosis markers levels, prevent liver fibrosis and hepatic microvascular dysfunction in liver fibrosis rats	Root of <i>Panax notoginseng</i> (Burk)F.H. Chen
Cordyceps polysaccharide [47,48]	Increase CD ₄ /CD ₈ T lymphocytes ratio and decrease HA and PC III, inhibit TGF- β 1 and PDGF expressions, reduce AST and ALT, apply to CHB patients	The complex of the stroma of the fungus <i>Cordiceps sinensis</i> (berk.)Sacc. and larva of caterpillar on which the fungus grows
<i>Ginkgo biloba</i> extract [49,50]	Reduce ALT and AST, anti-oxidation, suppress NF- κ B activation, inhibit TGF- β 1 and collagen gene expression in rats	Leaves of <i>Ginkgo bioba</i> L.
Artemisinin/artesunate [51]	As inhibitors of hepatitis B virus production	Aerial part of <i>Artemisia annua</i> L.
Berberis aristata fruit extract and berberine [52-62]	Reduce AST and ALT, anti-oxidation, suppress expression of NF- κ B, α -SMA, TGF- β 1, anti-liver cancer, induce apoptosis in cancer cell lines and animal models	Rhizome of <i>Coptis chinensis</i> French., <i>Coptis teeta</i> Wall., <i>Coptis japonica</i> Makino., other genus <i>Berberis</i>
Aucubin [63,64]	Reduce AST and ALT, against HBV replication, suppress NF- κ B activation in cell or animal models.	Ripe seed of <i>Plantago asiatica</i> L.
<i>Ganoderma lucidum</i> extract & <i>Ganoderma</i> polysaccharide [65,66]	Reduce AST, ALT, ALP, Tbil and the collagen content in rats with cirrhosis induced by biliary obstruction in rats, inhibit HSCs cells proliferation through blocking PDGF β R phosphorylation	<i>Ganoderma lucidum</i>
Gypenoside [67]	Inhibits HSCs proliferation, arrest HSC cells at G1 phase, inhibit the signal pathway of PDGF-Akt-p70 and down-regulate of cyclin D1 and D3 expression	<i>Gynostemma pentaphyllum</i>
<i>Solanum nigrum</i> Linn extract [68]	Reduce AST, ALT, ALP, Tbil, modulate GSTs and SOD, repress the production of free radicals	<i>Solanum nigrum</i> Linn

Table 2: Anti-fibrosis effect of composite formulae

Composite formulae and major references	Pharmacological actions and clinical indications	Compositions of formulae
Yinchenhao Tang [69-78]	Induce HSCs apoptosis, inhibit HSCs activation, reduce collagen deposition and α -SMA and decrease the serum level of HA, apply to postoperative biliary atresia patients and icteric patients with cirrhosis	<i>Herba Artemisiae Scopariae, Radix et Rhizoma Rhei, Fructus Gardeniae</i>
Xiao Chaihu Tang [79-90]	Inhibit TGF- β 1 and PDGF expressions, regulate MMPs/TIMPs balance, increase IL-12 production, suppress HSC activation, apply to CHC and CHB patients	<i>Radix Bupleuri, Radix Scutellariae, Rhizoma Pinelliae, Radix Ginseng, Fructus Jujubae, Radix Glycyrrhizae</i>
Buzhong Yiqi Tang [91,92]	Immunoregulation, inhibit TGF- β 1 and IL-13 production, apply to CHC patients	<i>Radix Astragali, Radix Glycyrrhizae, Radix Ginseng, Radix Angelicae Sinensis, Pericarpium citri reticulatae, Rhizoma Cimicifugae, Radix Bupleuri, Rhizoma Atractylodis macrocephalae</i>
Renshen Yangrong Tang [92-94]	Immunoregulation, inhibit TGF- β 1 and IL-13 production, apply to CHC patients	<i>Radix Astragali, Radix Angelicae sinensis, Cortex Cinnamomi, Radix Glycyrrhizae, Pericarpium citri reticulatae, Rhizoma Atractylodis macrocephalae, Radix Ginseng, Radix Paeoniae alba, Radix Rehmanniae, Fructus Schisandrae chinensis, Poria, Cortex et Radix Polygalae</i>
Fufang Jinsan E [95]	Inhibit TGF- β 1 and Smad3, Up-regulate Smad7 in liver fibrotic rats	<i>Radix Curcumae, Rhizoma Sparganii, Rhizoma Curcumae</i>
Denshen Taoxiong Tang [96]	Anti-ascites, regulate urine sodium concentration in liver fibrotic mouse	<i>Radix Salviae Miltiorrhizae, Semen Persicae, Rhizoma Chuanxiong</i>
Ershen Zezhu Tang [96]	Anti-ascites, regulate urine sodium concentration in liver fibrotic mouse	<i>Radix Codonopsis, Radix Salviae miltiorrhizae, Rhizoma Atractylodis macrocephalae, Rhizoma Alismatis</i>
Buqi Jianzhong Tang [97,98]	Diuretic effect, increase excretion Na ⁺ , reduce GPT and GOT, apply to cirrhosis ascites	<i>Largehead Atractylodis Rhizoma, Hoelen, Aurantii Nobilis Pericarpium, Radix Ginseng, Radix Scutellariae, Magnolia Bark, Alisma Rhizoma, Radix Ophiopogonis, Atractylodis Rhizoma</i>
Fangji Tang [97,98]	Diuretic effect, increase excretion Na ⁺ , reduce GPT and GOT, apply to cirrhosis ascites	<i>Sinomeni Claulis Et Rhizoma, Mori Context, Hoelen Preilla Herba, Saussurae Radis</i>
Handan Ganle [99-102]	Anti-oxidatation, collagenolytic effect, regulate MMPs/TIMPs balance, apply to CHB patients	<i>Radix Sophorae Flavescentis, Radix Salviae miltiorrhizae, Radix Paeoniae, Radix Astragali, Folium Ginkgo</i>
Ganzhifu [103]	Anti-oxidation, reduce collagens, anti-liver fibrosis in liver fibrotic rats	<i>Rhizoma Zingiberis, Ramulus Cinnmomi, Radix Aconiti Lateralis preparata, Radix Astragali, Radix Bupleuri, Fructus Aurantii, Rhizoma Atractylodis macrocephalae, Radix Glycyrrhizae</i>
Fuzheng Huay [104-108]	Significantly decrease HA, LM, P-III-P and IV-C content, improve serum Alb, ALT, AST, GGT, LM, HA, Hyp and ration of BCAA/AAA in animals and CHB patients. Inhibit HSCs activation via FN/integrin signaling.	<i>Radix Salvia miltiorrhizae, Cordyceps mycelia extract, Semen Persicae, Gynostemma Pentaphyllammak, Pollen Pini, Fructus schisandrae chinensis</i>

exhibit *in vitro* and *in vivo* inhibitory effects on TGF- β 1. Salvianolic acid B (SA-B) inhibits HSC proliferation and collagen production and decreases the cellular TGF- β 1 autocrine and Mitogen-Activated Protein Kinase (MAPK) activity, which may be the anti-fibrosis mechanism of SA-B [14,17]. Paclitaxel, a compound isolated from *Taxus brevifolia*, suppresses the TGF- β 1 signalling pathway between biliary epithelium cells and myofibroblasts and reduces collagen synthesis [120]. *Yinchenhao Tang* [71] regulates platelet-derived growth factor (PDGF)-BB-dependent signalling pathways of HSC in primary culture and attenuates the development of liver fibrosis induced by thioacetamide in rats. Among the components of

Yinchenhao Tang, 3-methyl-1,6,8-trihydroxyanthraquinone (emodin) derived from *Rhei rhizoma* is the most active compound [72]. Genipin, a metabolite derived from *Yinchenhao Tang*, suppresses wound-induced cell migration and proliferation and decreases collagen type I, TGF β 1 and α -smooth muscle actins (α -SMA) mRNA and protein expression [76]. Chen *et al.* [67] demonstrate that Gypenosides inhibits PDGF-induced HSCs proliferation through inhibiting the signalling pathway of PDGF-Akt-p70^{S6K} and down-regulating cyclin D1 and D3 expression. Another study shows that ganoderic acids and ganoderenic acids in *Ganoderma lucidum* (*Lingzhi*) extract significantly inhibit the proliferation of HSCs by attenuating the

Table 3: Anti-fibrosis effect of combinations of single compound and formulae or Chinese medicines and conventional medicines

Combination of drugs and major references	Clinical indications and pharmacological actions or side effects
ITF- α . injection + glycyrrhizin (Stronger Neo Minophagen C) injection [109]	CHC patients. With IFN therapy, ALT levels did not decrease more than 50%, while with IFN combined with SNMC therapy, ALT levels decreased approximately 70% in all patients (one became normal), but no other parameters were changed.
Ursodeoxycholic acid P.O + glycyrrhizin P.O [110]	CHC patients belong to interferon-resistant or unstable patients. Improving liver-specific enzyme abnormalities: AST, ALT and gamma-glutamyl transpeptidase, no change HCV-related factors or liver histology compared with control.
Matrine injection + <i>Xiao Chaihu Tang</i> P.O [111]	Liver fibrosis patients. Combination therapy improves AST, ALT and reduces HA, LN, CIV, TGF- β 1 and TNF- α .
IFN- γ or IFN- α . injection + <i>Xiao Chaihu Tang</i> (<i>Sho-saiko-to</i>) P.O [112-115]	CHB patients. Combination therapy improves AST, ALT, Tbil and has synergistic anti-fibrosis in biochemical parameters, but IFN and/or <i>Sho-saiko-to</i> may also induce acute interstitial pneumonitis.
Tiopronin P.O + <i>Xiao Chaihu Tang</i> P.O [116]	CHB patients. Synergistic effects in improving liver functions and fibrotic factors.
Lamivudine + <i>Radix Salviae Miltiorrhizae</i> [117]	CHB patients. Treatment with both drugs was better than one and more effective than the control group in parameters of liver function and liver fibrosis.
<i>Bushen</i> Granule (BSG) P.O + Marine Injection (MI) [118]	CHB patients. Combined treatment of BSG and MI was better than Lamivudine group in one year therapeutical course.

blockade of PDGF β R phosphorylation [66]. Chen *et al.* [88] show that 0.5 g/kg/day of *Xiao Chaihu Tang* significantly reduces the serum level of the N-terminal pro-peptide of collagen type III (PIII NP) and the mRNA expression of TGF- β 1 and PDGF in a rat bile duct ligated model.

Anti-apoptosis in hepatocyte and inducement of apoptosis in HSC

Yamamoto *et al.* [73] find that *Yinchenhao Tang* inhibits hepatocyte apoptosis induced by TGF- β 1 *in vitro*. Another study [74] demonstrates that pre-treatment with *Yinchenhao Tang* markedly suppresses liver apoptosis/injury. Genipin, which is a principal ingredient of *Yinchenhao Tang*, suppresses Fas-mediated apoptosis in primary-cultured murine hepatocytes *in vitro* [73]. The resistance to Ca²⁺-induced mitochondrial permeability transition (MPT) is enhanced in liver mitochondria of genipin-treated mice [74]. These results suggest that the anti-apoptotic activity of genipin via the interference with MPT is a possible mechanism for the therapeutic effects of *Yinchenhao Tang* and that *Yinchenhao Tang* and its ingredient genipin protect hepatocyte from liver apoptosis/injury. Conversely, activated HSC plays a pivotal role in hepatic fibrosis, HSC apoptosis is involved in the mechanisms of spontaneous resolution of rat hepatic fibrosis, and the agent that induces HSC apoptosis has been shown to reduce experimental hepatic fibrosis in rats [121]. Considerable interest has been generated in uncovering the molecular events that regulate HSC apoptosis and discovering drugs that can stimulate HSC apoptosis in a selective manner. Ikeda *et al.* [75] find that *Yinchenhao Tang* induces HSC apopto-

sis in a time- and concentration-dependent manner as judged by the nuclear morphology, quantitation of cytoplasmic histone-associated DNA oligonucleosome fragments and caspase-3 activity. Thus, the induction of HSC apoptosis may be the mechanism whereby *Yinchenhao Tang* treats hepatic fibrosis. Tetrandrine [29] also induces apoptosis of T-HSC/Cl-6 cells and induces the activation of caspase-3 protease and subsequent proteolytic cleavage of poly (ADP-ribose) polymerase.

Synergistic effects on liver fibrosis and carcinogenesis

Berberine derived from berberis markedly reduces viral production *in vitro* [51]. In liver damage induced by paracetamol or CCl₄, *Berberis aristata* fruit extract and berberine, its principal ingredient, show hepato-protective action [52,53]. Berberine also exhibits antioxidative effects on tert-butyl hydroperoxide-induced oxidative damage in rat liver [54] and in the lipopolysaccharide (LPS) plus ischemia-reperfusion model [55]. Berberine abolishes acetaldehyde-induced NF- κ B activity and cytokine production in a dose dependent manner, suggesting the potential role of berberine to treat alcoholic liver disease (ALD) [56]. In the rat liver fibrosis induced by multiple hepatotoxic factors (CCl₄, ethanol and high cholesterol), the serum levels of ALT and AST and the hepatic content of MDA and Hyp are markedly decreased, while the activity of hepatic SOD is significantly increased in berberine-treated groups in a dose-dependent manner. In addition, histopathological changes, such as steatosis, necrosis and myofibroblast proliferation, are reduced and the expression of α -SMA and TGF- β 1 is significantly down-regulated in the berberine-treated groups [57].

Clinically, berberine has been used in Japan to alleviate hypertyraminemia in patients with liver cirrhosis [58]. Berberine possesses anti-tumor effects in rats and mice with chemical-induced liver cancer [59] and anti-invasion in human lung cancer cell lines [60]. The mechanism may be related to its anti-inflammation effects [60,61]. The inhibitory effects of two different doses of berberine in human liver cancer HepG2 cell lines display different effects: in HepG2 cells treated with 24.0 mg/L of berberine, an increase in the sub G₀ phase that indicates cell death is observed in cell cycle analysis with flow cytometry, however, there is no significant increase in sub G₀ in HepG2 cells treated with 4.0 mg/L of berberine [62]. These results demonstrate that the dosage of berberine is a meaningful factor in liver diseases treatment. Composite formulae, such as *Xiao Chaihu Tang*, not only inhibit viral replication, ameliorate inflammation and enhance regeneration of hepatic cells, but also inhibit HSC proliferation, suppress intra- and extra-cellular secretion, decrease the secretion of collagen and promote its degradation and reabsorption [79-90]. Shimizu *et al.* [83] show that *Xiao Chaihu Tang* functions as a potent anti-fibrosis agent via the inhibition of oxidative stress in hepatocytes and HSCs and that its active components are baicalin and baicalein. It should be noted that baicalin and baicalein are flavonoids with chemical structures very similar to silybinin which possess anti-fibrogenic activities. Several composite formulae have been used to improve ascites induced by hepatic cirrhosis in chronic hepatitis B (CHB) or chronic hepatitis C (CHC) patients. We demonstrate that *Buqi Jianzhong Tang* and *Fangji Tang* increase Na⁺ excretion and urine volume and reduce GOT and GPT in rats with CCl₄-induced liver damage [89,98]. Most of the Chinese medicines in Tables 1 and 2 reduce serum enzymes, i.e. aspartate transaminase (AST) and alanine transaminase (ALT). A study with multivariate analysis demonstrates that the mode of therapy and ALT levels are significant factors affecting HCC development [26]. Glycyrrhizin administered as Stronger Neo Minophagen C (SNMC) and *Xiao Chaihu Tang* exhibit this effect [24-26,90] in long-term clinical trials. Considered to possess anti-carcinogenic properties, *Xiao Chaihu Tang* inhibits chemical hepatocarcinogenesis in animals, acts as a biological response modifier and suppresses the proliferation of hepatoma cells by inducing apoptosis and arresting the cell cycle. Among the active components of *Xiao Chaihu Tang*, baicalin, baicalein and saikosaponin have the ability to inhibit cell proliferation [90].

Efficiency and safety of Chinese medicines in treating liver fibrosis

Efficacy

Some anti-fibrosis Chinese medicines, such as Salvianolic acid B (SA-B), tetrandrine and oxymatrine, are clinically effective. SA-B reverses liver fibrosis in chronic hepatitis B

patients. SA-B reduces the serum HA content and decreases the overall serum fibrosis markers better than IFN- γ [14]. A multi-centre, randomized, double-blind, placebo-controlled clinical trial shows that oxymatrine effectively reduces the DNA replication of HBV [34,35] and the therapeutic effect is even stronger when used together with *Xiao Chaihu Tang* [110]. A double-blind, randomized, placebo-controlled phases I/II trial of intravenous glycyrrhizin for the treatment of chronic hepatitis C shows that glycyrrhizin lowers serum ALT and that the treatment has no effect on the RNA levels of HCV [23]. Long-term clinical trials in Japan and the Netherlands demonstrate that interferon non-responder patients with chronic hepatitis C and fibrosis stage 3 or 4 have a reduced incidence rate of HCC after glycyrrhizin therapy normalizes ALT levels [24,25].

In China and Japan, many composite formulae are used to treat liver fibrosis and cirrhosis (Table 2) and the pharmacological effects and mechanisms have been demonstrated [69-94]. Experimental and clinical studies show that *Handan Ganle* is effective [99-102]. *Fuzheng Huayu*, another modern formula, has also been intensively studied [104-107]. The results suggest that *Fuzheng Huayu*'s anti-fibrosis effects may be associated with the inhibition of liver collagen production [104]. Further study reveals that the conditioned medium from activated HSC stimulates the quiescent HSC proliferation and type I collagen secretion and that the drug serum inhibits this stimulating action and vascular endothelial growth factor (VEGF) secretion from the activated HSC. *Fuzheng Huayu* acts effectively against the autocrine activation pathway of HSC [105].

A recent study demonstrates the action of *Fuzheng Huayu* against HSC activation via the fibronectin/integrin-5 β 1 signalling pathway [107]. Another study shows that *Fuzheng Huayu* alleviates liver fibrosis without any adverse events [106]. A systematic review analyzes the efficacy and safety of *Fuzheng Huayu* in treatment of CHB fibrosis [108] based on clinical trials with placebo and/or random control (other positive Chinese medicines and conventional drugs). Seven studies on *Fuzheng Huayu* in the treatment of CHB fibrosis (total 590 cases) are included in the systematic review. This systematic review concludes that *Fuzheng Huayu* has significant improvement of serum fibrosis index and pathology of liver biopsy (class S in fibrosis) without observable adverse events, although some included studies are of low quality and are small randomized clinical trials.

The combined therapy with ursodeoxycholic acid and glycyrrhizin is safe and effective in improving liver-specific enzyme abnormalities, and may be an alternative to interferon in chronic hepatitis C viral infection, especially for

interferon-resistant or unstable patients [110]. The antiviral efficacy of *Bushen* granule (BSG) coupled with marine injection (MI) to treat chronic hepatitis B was more effective than lamivudine treatment [118]. Other reports of therapeutic value gained through combining conventional and Chinese medicines can be found in Table 3[112-117].

Safety

There have been reports on adverse events and hepatotoxicity caused by herbal medicines [122]. *Xiao Chaihu Tang*, used alone or in combination with interferon, may induce acute interstitial pneumonia in patients with chronic

active hepatitis [113,114]. Glycyrrhizin injection may induce fatal biliary cirrhosis [123]. A one-year study demonstrates that Chinese medicines caused hepatotoxicity in patients with chronic hepatitis B [124]. Some of hepatic veno-occlusive diseases have been ascribed to toxicity of herbs; however, the toxic compounds remain to be determined. Hepatic veno-occlusive disease may result from pyrrolizidine alkaloids which are found in numerous plants worldwide. Systematic toxicological knowledge of Chinese medicines is available [125].

Adverse events in the cases of herbal toxicity are in fact very complex. The fatal biliary cirrhosis case [123] was a




Figure 1
Research chart of Chinese medicines for liver fibrosis. The re-evaluation involved in pharmaceutical and medical research including herb quality control, mechanism study and clinical trial will be carried out on standardized international platforms.

50-year-old woman suffering from a diffuse skin rash, high fever and jaundice immediately after a second injection of glutathione and stronger neo-minophagen C, which contains glycyrrhizin. It is difficult to determine the cause of the adverse events to be indeed glycyrrhizin (which is extracted from *Glycyrrhiza uralensis*) for the following reasons: (1) no literature has shown the hepatotoxicity of glycyrrhizin until now; (2) stronger neo-minophagen C includes 0.1% cysteine and 2.0% glycine in physiological saline solution as well as 0.2% glycyrrhizin, and is also combined with glutathione; and (3) the clinical indication of glycyrrhizin was clear enough (glycyrrhizin is only used in chronic liver hepatitis without bile duct obstruction, which is *Yinchenhao Tang's* indication in Chinese medicine clinical practice), and glycyrrhizin has no anti-fibrotic effect in rats with fibrosis induced by bile duct ligation and scission [65].

Evidence against Chinese medicines

While ample evidence supports Chinese medicines in treating liver fibrosis, some recent reviews on clinical trials did not find significant effects. Levy *et al.* [126] review the use of silymarin, glycyrrhizin, *Xiao Chaihu Tang*, *Phyllanthus amarus*, *Picrorrhiza kurroa*, Compound 861, CH-100 and LIV.52 used to treat chronic liver diseases. Dhiman *et al.* [127] review *Phyllanthus*, *Silybum marianum* (milk thistle), glycyrrhizin and LIV.52 used to treat liver diseases. However, neither review recommends the use of herbal medicines to treat chronic liver diseases.

SA-B, Glycyrrhizin, *Xiao Chaihu Tang* and *Yinchenhao Tang* are used to treat chronic liver diseases in China and Japan. The major active herb is coptis, of which berberine is the major active component [128]. According to Chinese medicine theory, we use coptis to treat various liver diseases and cancer in Hong Kong [129]. We also propose to replace bear bile with coptis in Chinese medicine practice [130].

Further studies on pharmacological actions and clinical efficacies of the anti-fibrosis effects of Chinese medicines are warranted. Systematic reviews to evaluate clinical studies on the efficacy and safety of Chinese medicines are also necessary. An exemplifying strategy for these studies is demonstrated in Figure 1.

Conclusion

Evidence indicates that some Chinese medicines are clinically effective in treating liver fibrosis. Strict quality control of Chinese medicines is critical [131] for pharmacological, clinical and in-depth mechanism studies [132]. Experiments and clinical trials should be carried out on the platforms that conform to international standards [133].

Abbreviations

ECM: extracellular matrix; HSC: hepatic stellate cell; CAM: complementary and alternative medicine; SA-B: salvianolic acid B; HBV: hepatitis B virus; HCV: hepatitis C virus; CHB: chronic hepatitis B; CHC: chronic hepatitis C; AST (= GOT): aspartate aminotransferase; ALT (= GPT): alanine aminotransferase; TGF- β 1: transforming growth factor beta1; Smad3: SMAD family member 3; Smad7: SMAD family member 7; smurf2: Smad ubiquitination regulatory factor 2; TIMP: tissue inhibitors of metalloproteinases; MMP: matrix metalloproteinase; MAPK: mitogen-activated protein kinase; NF- κ B: nuclear factor- κ B; PDGF: platelet-derived growth factor; PPAR γ : proliferator-activated receptor gamma; SOD: superoxide dismutase; Hyp: hydroxyproline; HA: hyaluronic acid; α -SMA: α -smooth muscle actin; IFN- γ : interferon-gamma; IFN- α : interferon-alfa; LN: laminin; PCIII: type III procollagen; CIV: type IV collagen; Tbil: total bilirubin; TNF- α : tumor necrosis factor alfa; PIIINP: the N-terminal pro-peptide of collagen type III; MPT: mitochondrial permeability transition; Alb: albumin; BCAA: branched chain amino acid; AAA: aromatic amino acid; FN/integrin: fibronectin (FN)-integrin-5 β 1 complex.

Competing interests

Fuzhen Huayu is a herbal product developed by PL's institution at the Shanghai University of Traditional Chinese Medicine. The authors declare that they have no competing interests for other Chinese medicines discussed in the present study.

Authors' contributions

YBF and YT conceived the study, interpreted the data and revised the manuscript. YBF retrieved and analyzed the data and drafted the manuscript. KFC and NW retrieved the data from Chinese journals and translated them into English. PL and TN supervised some of the experiments. All authors read and approved the final version of the manuscript.

Acknowledgements

The study was financially supported by grants from the Research Council of the University of Hong Kong (Project Codes: I0208005 and I0400413), the University Grants Committee (UGC) of Hong Kong (Project Code: 764708M), the Pong Ding Yuen Endowment Fund for Education and Research in Chinese-Western Medicine (Project Code: 20005274) and the Government-Matching Grant Scheme (4th Phase, Project Code: 20740314). The authors would like to thank Prof SP Lee and Dr GKK Lau for their assistance in revising the manuscript.

References

1. Yuen MF, Lai CL: **Natural history of chronic hepatitis B virus infection.** *J Gastroenterol Hepatol* 2000, **15**(Suppl):E20-4.
2. Seeff LB, Hoofnagle JH: **The national institutes of health consensus development conference management of hepatitis C 2002.** *Clin Liver Dis* 2003, **7**:261-87.
3. Koike K: **Antiviral treatment of hepatitis C: present status and future prospects.** *J Infect Chemother* 2006, **12**:227-32.

4. Tsukamoto H, Lu SC: **Current concepts in the pathogenesis of alcoholic liver injury.** *FASEB J* 2001, **15**:1335-49.
5. Heidebaugh JJ, Brudery M: **Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation.** *Am Fam Physician* 2006, **74**:756-62.
6. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: **The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.** *J Hepatol* 2006, **45**:529-38.
7. Wells RG: **The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis.** *J Clin Gastroenterol* 2005, **39**:158-61.
8. Friedman SL: **Liver fibrosis—from bench to bedside.** *J Hepatol* 2003, **38**(Suppl 1):38-53.
9. Friedman SL: **Reversibility of hepatic fibrosis and cirrhosis—is it all hype?** *Nat Clin Pract Gastroenterol Hepatol* 2007, **4**(5):236-7.
10. Schuppan D, Jia JD, Brinkhaus B, Hahn EG: **Herbal products for liver diseases: a therapeutic challenge for the new millennium.** *Hepatol* 1999, **30**(4):1099-104.
11. Shimizu I: **Antifibrogenic therapies in chronic HCV infection.** *Infect Disord Drug Targets* 2001, **1**(2):227-40.
12. Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH: **Complementary and alternative medicine in chronic liver disease.** *Hepatology* 2001, **34**(3):595-603.
13. Xie HM, Hu YY, Gu HT, Nagano Y, Ji G, Liu P: **Study of Salviae miltiorrhizae on liver fibrosis in rats induced by CCl4 and DMN.** *Zhongxiyi Jiehe Ganbing Zazhi* 1999, **9**:16-8.
14. Liu P, Hu YY, Liu C, Zhu DY, Xue HM, Xu ZQ, Xu LM, Liu CH, Gu HT, Zhang ZQ: **Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B.** *World J Gastroenterol* 2002, **8**:679-85.
15. Lee TY, Wang GJ, Chiu JH, Lin HC: **Long-term administration of Salvia miltiorrhiza ameliorates carbon tetrachloride-induced hepatic fibrosis in rats.** *J Pharm Pharmacol* 2003, **55**:1561-8.
16. Wang H, Chen XP, Qiu FZ: **Salviae miltiorrhizae ameliorates cirrhosis and portal hypertension by inhibiting nitric oxide in cirrhotic rats.** *Hepatobiliary Pancreat Dis Int* 2003, **2**:391-6.
17. Zhao JF, Liu CH, Hu YY, Xu LM, Liu P, Liu C: **Effect of salvianolic acid B on Smad3 expression in hepatic stellate cells.** *Hepatobiliary Pancreat Dis Int* 2004, **3**:102-5.
18. Lee TY, Chang HH, Wang GJ, Chiu JH, Yang YY, Lin HC: **Water-soluble extract of Salvia miltiorrhiza ameliorates carbon tetrachloride-mediated hepatic apoptosis in rats.** *J Pharm Pharmacol* 2006, **58**:659-65.
19. Yamamura Y, Kotaki H, Tanaka N, Aikawa T, Sawada Y, Iga T: **The pharmacokinetics of glycyrrhizin and its restorative effect on hepatic function in patients with chronic hepatitis and in chronically carbon-tetrachloride-intoxicated rats.** *Biopharm Drug Dispos* 1997, **18**:717-25.
20. Wang JY, Guo JS, Li H, Liu SL, Zern MA: **Inhibitory effect of glycyrrhizin on NF-kappaB binding activity in CCl4- plus ethanol-induced liver cirrhosis in rats.** *Liver* 1998, **18**:180-5.
21. Iino S, Tango T, Matsushima T, Toda G, Miyake K, Hino K, Kumada H, Yasuda K, Kuroki T, Hirayama C, Suzuki H: **Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis.** *Hepatol Res* 2001, **19**:31-40.
22. Cai Y, Shen SZ, Wang JY: **Effects of glycyrrhizin on genes expression during the process of liver fibrosis.** *Zhonghua Yixue Zazhi* 2003, **83**:1122-5.
23. Rossum Van TGJ, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW: **Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double blind, randomised, placebo controlled phase I/II trial.** *J Gastroenterol Hepatol* 1999, **14**:1093-9.
24. Veldt BJ, Hansen BE, Ikeda K, Verhey E, Suzuki H, Schalm SW: **Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon.** *Scand J Gastroenterol* 2006, **41**:1087-94.
25. Ikeda K, Arase Y, Kobayashi M, Saitoh S, Someya T, Hosaka T, Sezaki H, Akuta N, Suzuki Y, Suzuki F, Kumada H: **A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients.** *Dig Dis Sci* 2006, **51**:603-9.
26. Rino Y, Tarao K, Morinaga S, Ohkawa S, Miyakawa K, Hirokawa S, Masaki T, Tarao N, Yukawa N, Saeki H, Takashi Y, Imada T: **Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.** *Anticancer Res* 2006, **26**(3B):2221-6.
27. Wang ZR, Chen XM, Li DG: **Tetrandrine inhibits expressions of c-fos and c-jun mRNA in fibrosis liver of rats.** *Shanghai Yixue* 2003, **26**:332-4.
28. Wang H, Chen XP, Qiu FZ: **Tetrandrine increased hepatic expression of nitric oxide synthase type II in cirrhotic rats.** *World J Gastroenterol* 2004, **10**:1923-7.
29. Zhao YZ, Kim JY, Park EJ, Lee SH, Woo SW, Ko G, Sohn DH: **Tetrandrine induces apoptosis in hepatic stellate cells.** *Phytother Res* 2004, **18**:306-9.
30. Chen YW, Li DG, Wu JX, Chen YW, Lu HM: **Tetrandrine inhibits activation of rat hepatic stellate cells stimulated by transforming growth factor-beta in vitro via up-regulation of Smad 7.** *J Ethnopharmacol* 2005, **100**:299-305.
31. Hsu YC, Chiu YT, Lee CY, Wu CF, Huang YT: **Anti-fibrotic effects of tetrandrine on bile-duct ligated rats.** *Can J Physiol Pharmacol* 2006, **84**:967-76.
32. Hsu YC, Chiu YT, Cheng CC, Wu CF, Lin YL, Huang YT: **Antifibrotic effects of tetrandrine on hepatic stellate cells and rats with liver fibrosis.** *J Gastroenterol Hepatol* 2007, **22**:99-111.
33. Zhang JP, Zhang M, Zhou JP, Liu FT, Zhou B, Xie WF, Guo C: **Anti-fibrotic effects of matrine on in vitro and in vivo models of liver fibrosis in rats.** *Acta Pharmacol Sin* 2001, **22**:183-6.
34. Chen YX, Mao BY, Jiang JH: **Relationship between serum load of HBV-DNA and therapeutic effect of oxymatrine in patients with chronic hepatitis B.** *Zhongguo Zhongxiyi Jiehe Zazhi* 2002, **22**:335-6.
35. Mao YM, Zeng MD, Lu LG: **Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: a randomized, double blind, placebo-controlled, multicenter clinical study.** *World J Gastroenterol* 2004, **10**:3269-73.
36. Kato J, Ido A, Hasuike S, Uto H, Hori T, Hayashi K, Murakami S, Terano A, Tsubouchi H: **Transforming growth factor-beta-induced stimulation of formation of collagen fiber network and anti-fibrotic effect of taurine in an in vitro model of hepatic fibrosis.** *Hepatol Res* 2004, **30**:34-41.
37. Miyazaki T, Karube M, Matsuzaki Y, Ikegami T, Doy M, Tanaka N, Bouscarel B: **Taurine inhibits oxidative damage and prevents fibrosis in carbon tetrachloride-induced hepatic fibrosis.** *J Hepatol* 2005, **43**:117-25.
38. Chen ZZ, Wang H: **Inhibitory Effects of tetramethylpyrazine on experimental hepatic fibrosis in rats.** *Zhong Xi Yi Jiehe Ganbing Zazhi* 1997, **7**:156-8.
39. Tan LX, Li XS, Liu ZQ, Liu LY: **Effects of combination therapy of rehlin and tetramethylpyrazine on experimental hepatic fibrosis induced by tetrachloride.** *Zhonghua Ganzangbing Zazhi* 2004, **12**:692-3.
40. Zhan Y, Li D, Wei H, Wang Z, Huang X, Xu Q, Lu H: **Emodin on hepatic fibrosis in rats.** *Chin Med J (Engl)* 2000, **113**:599-601.
41. Zhan YT, Liu B, Li DG, Bi CS: **Mechanism of emodin for anti-fibrosis of liver.** *Zhonghua Ganzangbing Zazhi* 2004, **12**:245-6.
42. Yang W, Chen H, Jiang Y: **Inhibitive effect of curcumin and amiloride on the fibrosis of rat hepatic stellate cells induced by oxidative stress.** *Zhongyao Cai* 2003, **26**:795-8.
43. Zheng S, Chen A: **Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro.** *Biochem J* 2004, **384**:149-57.
44. Lin CF, Wong KL, Wu RS, Huang TC, Liu CF: **Protection by hot water extract of Panax notoginseng on chronic ethanol-induced hepatotoxicity.** *Phytother Res* 2003, **17**:1119-22.
45. Shii XF, Liu Q, Liu L, Xu M: **Effect of total saponin of Panax Notoginseng on liver fibrosis in rats.** *Zhongyao Yaoli yu Linchuang* 2004, **20**:12-4.
46. Park WH, Lee SK, Kim CH: **A Korean herbal medicine, Panax notoginseng, prevents liver fibrosis and hepatic microvascular dysfunction in rats.** *Life Sci* 2005, **76**(15):1675-90.
47. Gong HY, Wang KQ, Tang SG: **Effects of cordyceps sinensis on T lymphocyte subsets and hepatofibrosis in patients with chronic hepatitis B.** *Hunan Yike Daxue Xuebao* 2000, **25**:248-50.
48. Liu YK, Shen W: **Inhibitive effect of cordyceps sinensis on experimental hepatic fibrosis and its possible mechanism.** *World J Gastroenterol* 2003, **9**:529-33.
49. Ding J, Yu J, Wang C, Hu W, Li D, Luo Y, Luo H, Yu H: **Ginkgo biloba extract alleviates liver fibrosis induced by CCl4 in rats.** *Liver International* 2005, **25**:1224-32.

50. Liu SQ, Yu JP, Chen HL, Luo HS, Chen SM, Yu HG: **Therapeutic effects and molecular mechanisms of Ginkgo biloba extract on liver fibrosis in rats.** *Am J Chin Med* 2006, **34**:99-114.
51. Romero MR, Efferth T, Serrano MA, Castano B, Macias RI, Briz O, Marin JJ: **Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system.** *Antiviral Res* 2005, **68**:75-83.
52. Gilani AH, Janbaz KH: **Preventive and curative effects of berberis aristata fruit extract on paracetamol- and CCl₄-induced hepatotoxicity.** *Phytotherapy Res* 1995, **9**:489-94.
53. Janbaz KH, Gilani AH: **Studies on preventive and curative effects of berberine on chemical-induced hepatotoxicity in rodents.** *Fitoterapia* 2000, **71**:25-33.
54. Hwang JM, Wang CJ, Chou FP, Tseng TH, Hsieh YS, Lin WL, Chu CY: **Inhibitory effect of berberine on tert-butyl hydroperoxide-induced oxidative damage in rat liver.** *Arch Toxicol* 2002, **76**:664-70.
55. Yokozawa T, Ishida A, Kashiwada Y, Cho Ej, Kim Hy, Ikeshiro Y: **Copitidis Rhizoma: protective effects against peroxynitrite-induced oxidative damage and elucidation of its active components.** *J Pharm Pharmacol* 2004, **56**:547-56.
56. Hsiang CY, Wu SL, Cheng SE, Ho TY: **Acetaldehyde-induced interleukin-1beta and tumor necrosis factor-alpha production is inhibited by berberine through nuclear factor-kappaB signaling pathway in HepG2 cells.** *J Biomed Sci* 2005, **12**:791-801.
57. Zhang BJ, Xu D, Guo Y, Ping J, Chen LB, Wang H: **Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors.** *Clin Exp Pharmacol Physiol* 2008, **35**(3):303-9.
58. Watanabe A, Obata T, Nagashima H: **Berberine therapy of hypertryptaminemia in patients with liver cirrhosis.** *Acta Med Okayama* 1982, **36**(4):277-81.
59. Anis KV, Rajeshkumar NV, Kuttan R: **Inhibition of chemical carcinogenesis by berberine in rats and mice.** *J Pharm Pharmacol* 2001, **53**:763-8.
60. Peng PL, Hsieh YS, Wang CJ, Hsu JL, Chou FP: **Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.** *Toxicol Appl Pharmacol* 2006, **214**:8-15.
61. Kuo CL, Chi CW, Liu TY: **The anti-inflammatory potential of berberine in vitro and in vivo.** *Cancer Lett* 2004, **203**:127-37.
62. Tan YI, Goh D, Ong ES: **Investigation of differentially expressed proteins due to the inhibitory effects of berberine in human liver cancer cell line HepG2.** *Mol Biosyst* 2006, **2**:250-8.
63. Chang IM: **Liver-protective activities of aucubin derived from traditional oriental medicine.** *Res Commun Mol Pathol Pharmacol* 1998, **102**:189-204.
64. Park KS, Chang IM: **Anti-inflammatory activity of aucubin by inhibition of tumor necrosis factor-alpha production in RAW 264.7 cells.** *Planta Med* 2004, **70**:778-9.
65. Park EJ, Ko G, Kim J, Sohn DH: **Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, glycyrrhizin, and pentoxifylline in rats with cirrhosis induced by biliary obstruction.** *Biol Pharm Bull* 1997, **20**:417-20.
66. Wang GJ, Huang YJ, Chen DH, Lin YL: **Ganoderma lucidum extract attenuates the proliferation of hepatic stellate cells by blocking the PDGF receptor.** *Phytother Res* 2008, **23**:833-9.
67. Chen MH, Chen SH, Wang QF, Chen JC, Chang DC, Hsu SL, Chen CH, Sheue CR, Liu YW: **The molecular mechanism of gypenosides-induced GI growth arrest of rat hepatic stellate cells.** *J Ethnopharmacol* 2008, **117**:309-17.
68. Lin HM, Tseng HC, Wang CJ, Lin JJ, Lo CW, Chou FP: **Hepatoprotective effects of Solanum nigrum Linn extract against CCl₄-induced oxidative damage in rats.** *Chem Biol Interact* 2008, **171**:283-93.
69. Kobayashi H, Horikoshi K, Yamataka A, Lane GJ, Yamamoto M, Miyano T: **Beneficial effect of a traditional herbal medicine (inchin-ko-to) in postoperative biliary atresia patients.** *Pediatr Surg Int* 2001, **17**:386-9.
70. Sakaida I, Tsuchiya M, Kawaguchi K, Kimura T, Terai S, Okita K: **Herbal medicine Inchin-ko-to (TJ-135) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet.** *J Hepatol* 2003, **38**:762-9.
71. Imanishi Y, Maeda N, Otagawa K, Seki S, Matsui H, Kawada N, Arakawa T: **Herb medicine Inchin-ko-to (TJ-135) regulates PDGF-BB-dependent signaling pathways of hepatic stellate cells in primary culture and attenuates development of liver fibrosis induced by thioacetamide administration in rats.** *J Hepatol* 2004, **41**:242-50.
72. Inao M, Mochida S, Matsui A, Eguchi Y, Yulutz Y, Wang Y, Naiki K, Kakinuma T, Fujimori K, Nagoshi S, Fujiwara K: **Japanese herbal medicine Inchin-ko-to as a therapeutic drug for liver fibrosis.** *J Hepatol* 2004, **41**:584-91.
73. Yamamoto M, Ogawa K, Morita M, Fukuda K, Komatsu Y: **The herbal medicine Inchin-ko-to inhibits liver cell apoptosis induced by transforming growth factor beta 1.** *Hepatology* 1996, **23**:552-9.
74. Yamamoto M, Miura N, Ohtake N, Amagaya S, Ishige A, Sasaki H, Komatsu Y, Fukuda K, Ito T, Terasawa K: **Genipin, a metabolite derived from the herbal medicine Inchin-ko-to, and suppression of Fas-induced lethal liver apoptosis in mice.** *Gastroenterology* 2000, **118**:380-9.
75. Ikeda H, Nagashima K, Yanase M, Tomiya T, Arai M, Inoue Y, Teijima K, Nishikawa T, Watanabe N, Kitamura K, Isono T, Yahagi N, Noiri E, Inao M, Mochida S, Kume Y, Yatomi Y, Nakahara K, Omata M, Fujiwara K: **The herbal medicine inchin-ko-to (TJ-135) induces apoptosis in cultured rat hepatic stellate cells.** *Life Sci* 2006, **78**:2226-33.
76. Kitano A, Saika S, Yamanaka O, Ikeda K, Reinach PS, Nakajima Y, Okada Y, Shirai K, Ohnishi Y: **Genipin suppresses subconjunctival fibroblast migration, proliferation and myofibroblast transdifferentiation.** *Ophthalmic Res* 2006, **38**(6):355-60.
77. Lee TY, Chang HH, Chen JH, Hsueh ML, Kuo JJ: **Herb medicine Yin-Chen-Hao-Tang ameliorates hepatic fibrosis in bile duct ligation rats.** *J Ethnopharmacol* 2007, **109**:318-24.
78. Lee TY, Chang HH, Kuo JJ, Shen JJ: **Changes of hepatic proteome in bile duct ligated rats with hepatic fibrosis following treatment with Yin-Chen-Hao-Tang.** *Int J Mol Med* 2009, **23**:477-84.
79. Miyamura M, Ono M, Kyotani S, Nishioka Y: **Effects of sho-saiko-to extract on fibrosis and regeneration of the liver in rats.** *J Pharm Pharmacol* 1998, **50**:97-105.
80. Sakaida I, Matsumura Y, Akiyama S, Hayashi K, Ishige A, Okita K: **Sakaido Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet.** *J Hepatol* 1998, **28**:298-306.
81. Kayano K, Sakaida I, Uchida K, Okita K: **Inhibitory effects of the herbal medicine Sho-saiko-to (TJ-9) on cell proliferation and procollagen gene expressions in cultured rat hepatic stellate cells.** *J Hepatol* 1998, **29**:642-9.
82. Yamashiki M, Nishimura A, Huang XX, Nobori T, Sakaguchi S, Suzuki H: **Effects of the Japanese herbal medicine "Sho-saiko-to" (TJ-9) on interleukin-12 production in patients with HCV-positive liver cirrhosis.** *Dev Immunol* 1999, **7**:17-22.
83. Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, Yasuda M, Shiba M, Horie T, Amagaya S, Kawada N, Hori H, Ito S: **Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats.** *Hepatology* 1999, **29**(1):149-60.
84. Ono M, Miyamura M, Kyotani S, Saibara T, Ohnishi S, Nishioka Y: **Effects of Sho-saiko-to extract on liver fibrosis in relation to the changes in hydroxyproline and retinoid levels of the liver in rats.** *J Pharm Pharmacol* 1999, **51**:1079-84.
85. Kusunose M, Qiu B, Cui T, Hamada A, Yoshioka S, Ono M, Miyamura M, Kyotani S, Nishioka Y: **Effect of Sho-saiko-to extract on hepatic inflammation and fibrosis in dimethylnitrosamine induced liver injury rats.** *Biol Pharm Bull* 2002, **25**(11):1417-21.
86. Kitade Y, Watanabe S, Masaki T, Nishioka M, Nishino H: **Inhibition of liver fibrosis in LEC rats by a carotenoid, lycopene, or a herbal medicine, Sho-saiko-to.** *Hepato Res* 2002, **22**:196-205.
87. Sakaida I, Hironaka K, Kimura T, Terai S, Yamasaki T, Okita K: **Herbal medicine Sho-saiko-to (TJ-9) increases expression matrix metalloproteinases (MMPs) with reduced expression of tissue inhibitor of metalloproteinases (TIMPs) in rat stellate cell.** *Life Sci* 2004, **74**:2251-63.
88. Chen MH, Chen JC, Tsai CC, Wang WC, Chang DC, Tu DG, Hsieh HY: **The role of TGF-beta 1 and cytokines in the modulation of liver fibrosis by Sho-saiko-to in rat's bile duct ligated model.** *J Ethnopharmacol* 2005, **97**(1):7-13.
89. Kakumu S, Yoshioka K, Wakita T, Ishikawa T: **Effect of TJ-9 Sho-saiko-to (Kampo medicine) on interferon gamma and antibody production specific for hepatitis B virus antigen in**

- patients with type B chronic hepatitis. *Int Immunopharmacol* 1991, **13**:141-6.
90. Shimizu I: **Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma.** *J Gastroenterol Hepatol* 2000, **15**(Suppl):D84-90.
 91. Abe S, Ishibashi H, Tansho S, Hanazawa R, Komatsu Y, Yamaguchi H: **Protective effect of oral administration of several traditional Kampo-medicines on lethal Candida infection in immunosuppressed mice.** *Nippon Ishinkin Gakkai Zasshi* 2000, **41**:115-9.
 92. Ochi T, Kawakita T, Nomoto K: **Effects of Hochu-ekki-to and Ninjin-youei-to, traditional Japanese medicines, on porcine serum-induced liver fibrosis in rats.** *Immunopharmacol Immunotoxicol* 2004, **26**:285-98.
 93. Cyong JC, Ki SM, Iijima K, Kobayashi T, Furuya M: **Clinical and pharmacological studies on liver diseases treated with Kampo herbal medicine.** *Am J Chin Med* 2000, **28**:351-60.
 94. Suzuki M, Sasaki K, Yoshizaki F, Oguchi K, Fujisawa M, Cyong JC: **Anti-hepatitis C virus effect of citrus unshiu peel and its active ingredient nobiletin.** *Am J Chin Med* 2005, **33**:87-94.
 95. Song SL, Gong ZJ, Zhang QR: **Therapeutic effect and mechanism of traditional Chinese compound decoction of Radix Curcumae, Rhizoma Sparganii, Rhizoma Zedoariae on fibrotic liver in rats.** *Zhong Caoyao* 2004, **35**:293-6.
 96. Lu ZL, Li JC, Liu JD: **Experimental study of effects of TCM formulas on regulation of peritoneal lymphatic stomata and urine sodium in liver fibrosis mouse model.** *Zhongguo Zhongyiyao Xinxizazhi* 2000, **7**:25-6.
 97. Feng Y, Nagamatsu T, Suzuki Y, Kawata T, Koike T: **The diuretic effects of Wakan-yaku prescription on normal rats and various pathological models.** *Wakan Iyakugaku Zasshi* 1996, **13**:484-485.
 98. Feng Y, Nagamatsu T, Suzuki Y, Kawata T, Feng YG, Kobayashi S, Koike T: **Pharmacological studies of diuretic Wakan-yaku formulations: its application and evaluation of Pharmacological screening.** *Wakan Iyakugaku Zasshi* 2000, **17**:122-30.
 99. Li CX, Li L, Lou J, Yang WX, Lei TW, Li YH, Liu J, Cheng ML, Huang LH: **The protective effects of traditional Chinese medicine prescription, han-dan-gan-le, on CCl4-induced liver fibrosis in rats.** *Am J Chin Med* 1998, **26**:325-32.
 100. Li C, Luo J, Li L, Cheng M, Huang N, Liu J, Waalkes MP: **The collagenolytic effects of the traditional Chinese medicine preparation, Han-Dan-Gan-Le, contribute to reversal of chemical-induced liver fibrosis in rats.** *Life Sci* 2003, **72**:1563-71.
 101. Yang Q, Xie RJ, Geng XX, Luo XH, Han B, Cheng ML: **Effect of Danshao Huaxian capsule on expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in fibrotic liver of rats.** *World J Gastroenterol* 2005, **11**:4953-6.
 102. Cheng ML, Lu T, Yao YM, Geng XX: **Danshao huaxian capsule in treatment of decompensated cirrhosis resulting from chronic hepatitis B.** *Hepatobiliary Pancreat Dis Int* 2006, **5**:48-51.
 103. Wang LC, Zhao LS, Tang H: **Experimental study of liver fibrosis reversal effect of warming-yang compound formula ganzhifu.** *Zhongguo Zhongxiyi Jiehe Zazhi* 2006, **26**:63-7.
 104. Liu C, Liu P, Liu CH, Zhu XQ, Ji G: **Effects of Fuzhenghuayu decoction on collagen synthesis of cultured hepatic stellate cells, hepatocytes and fibroblasts in rats.** *World J Gastroenterol* 1998, **4**:548-549.
 105. Liu C, Jiang CM, Liu CH, Liu P, Hu YY: **Effect of Fuzhenghuayu decoction on vascular endothelial growth factor secretion in hepatic stellate cells.** *Hepatobiliary Pancreat Dis Int* 2002, **1**:207-10.
 106. Liu P, Hu YY, Liu C, Xu LM, Liu CH, Sun KW, Hu DC, Yin YK, Zhou XQ, Wan MB, Cai X, Zhang ZQ, Ye J, Zhou RX, He J, Tang BZ: **Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B.** *World J Gastroenterol* 2005, **11**:2892-9.
 107. Liu CH, Hu YY, Xu LM, Liu C, Liu P: **Effect of Fuzheng Huayu formula and its actions against liver fibrosis.** *Chin Med* 2009, **4**:12.
 108. He Q, Yang DG, Li L, Zhong BL, Zeng XM: **The 24 week effectiveness of Fuzheng Huayu capsule for CHB liver fibrosis: a systematic assessment.** *Zhongguo Xunzheng Yixue Zazhi* 2008, **8**:892-7.
 109. Okuno T, Arai K, Shindo M: **Efficacy of interferon combined glycyrrhizin therapy in patients with chronic hepatitis C resistant to interferon therapy.** *Nippon Rinsho* 1994, **52**:1823-7.
 110. Tsubota A, Kumada H, Arase Y, Chayama K, Saitoh S, Ikeda K, Kobayashi M, Suzuki Y, Murashima N: **Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients.** *Eur J Gastroenterol Hepatol* 1999, **11**:1077-83.
 111. Sun WH, Song MQ, Liu ZJ: **Combination therapy for hepatic fibrosis in 64 patients with hepatitis using Xiao-chai-hu-tang and Matrine injection.** *Zhongxiyi Jiehe Ganbing Zazhi* 2003, **13**:41-2.
 112. Li Z, Liao HH, Wu MJ, Lin ZH: **Study of combination therapy of Interferon-gamma and Xiao-chai-hu-tang for patients with liver fibrosis.** *Zhongxiyi Jiehe Ganbing Zazhi* 2001, **11**(Suppl):95.
 113. Xiong F, Sun J, Xiong W: **Clinical observation of combination therapy of Interferon and Xiao-chai-hu-tang for patients with liver fibrosis.** *Hubei Zhongyi Zazhi* 2003, **25**:10-11.
 114. Nakagawa A, Yamaguchi T, Takao T, Amano H: **Five cases of drug-induced pneumonitis due to Sho-saiko-to or interferon-alpha or both.** *Nihon Kyobu Shikkan Gakkai Zasshi* 1995, **33**(12):1361-1366.
 115. Ishizaki T, Sasaki F, Ameshima S, Shiozaki K, Takahashi H, Abe Y, Ito S, Kuriyama M, Nakai T, Kitagawa M: **Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis.** *Eur Respir J* 1996, **9**:2691-6.
 116. Liu AL, Wei M, Zeng ZG, Sun JX, Yang M, Yan SY: **Combination therapy of Xiao-chai-hu-tang and Tiopronin for patients with liver fibrosis.** *Shaanxi Zhongyi* 2005, **26**:873-4.
 117. Chen YS: **The efficacy of combining Lamivudine with Salvia miltiorrhiza on the treatment of chronic hepatitis B liver fibrosis.** *Redai Yixue Zazhi* 2003, **3**:207-9.
 118. Chen JJ, Tang BX, Wang LT, Chen XR: **Clinical study on effect of bushen granule combined with marine injection in treating chronic hepatitis B of Gan-shen deficiency with damp-heat syndrome type.** *Zhongguo Zhongxiyi Jiehe Zazhi* 2006, **26**:23-7.
 119. Liu X, Hu H, Yin JQ: **Therapeutic strategies against TGF-beta signalling pathway in hepatic fibrosis.** *Liver Int* 2006, **26**:8-22.
 120. Choi HS, Savard CE, Choi JW, Kuver R, Lee SP: **Paclitaxel interrupts TGF-beta1 signaling between gallbladder epithelial cells and myofibroblasts.** *J Surg Res* 2007, **141**:183-91.
 121. Elsharkawy AM, Oakley F, Mann DA: **The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis.** *Apoptosis* 2005, **10**:927-39.
 122. Stickele F, Patsenker E, Schuppan D: **Herbal hepatotoxicity.** *J Hepatol* 2005, **43**:901-10.
 123. Ishii M, Miyazaki Y, Yamamoto T, Miura M, Ueno Y, Takahashi T, Toyota T: **A case of drug-induced ductopenia resulting in fatal biliary cirrhosis.** *Liver* 1993, **13**:227-31.
 124. Yuen MF, Tam S, Fung J, Wong DK, Wong BC, Lai CL: **Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study.** *Aliment Pharmacol Ther* 2006, **24**:1179-86.
 125. Feng Y: *Basic and Clinical Toxicology of Chinese Medicines* Hong Kong: Commercial Press; 2009 in press.
 126. Levy C, Seeff LD, Lindor KD: **Use of herbal supplements for chronic liver diseases.** *Clin Gastroenterol Hepatol* 2004, **2**:947-56.
 127. Dhiman RK, Chawla YK: **Herbal medicines for liver diseases.** *Dig Dis Sci* 2005, **50**:1807-12.
 128. Ye X, Feng Y, Tong Y, Ng KM, Tsao SW, Lau GKK, Sze C, Zhang Y, Tang J, Shen J, Kobayashi S: **Hepatoprotective effects of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced acute liver hepatotoxicity in rats.** *J Ethnopharmacol* 2009, **124**:130-6.
 129. Feng Y, Luo WQ, Zhu SQ: **Explore new clinical application of Huanglian and corresponding compound prescriptions from their traditional use.** *Zhongguo Zhongyao Zazhi* 2008, **33**:1221-5.
 130. Feng Y, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, Tong Y: **Bear bile: dilemma of traditional medicinal use and animal protection.** *J Ethnobiol Ethnomed* 2009, **5**:2.
 131. Zhao ZZ, Hu YN, Liang ZT, Yuen JPS, Jian ZH, Lueng KSY: **Authentication is fundamental for standardization of Chinese Medicines.** *Planta Medica* 2006, **72**:1-10.
 132. Geerts A, Rogiers V, Sho-saiko-to: **the right blend of Traditional oriental medicine and liver cell biology.** *Hepatology* 1999, **29**:282-3.
 133. Angell M, Kassirer JP: **Alternative medicine-the risks of untested and unregulated remedies (Editorial).** *N Engl J Med* 1998, **339**:839-41.